Sequential alternation of nal-IRI/5-FU and gemcitabine/nab-paclitaxel versus nal-IRI/5-FU versus gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer: results of the randomized phase II PRODIGE 61-FUNGEMAX trial (France).
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 42256682.
- Also identified by DOI 10.1016/j.eclinm.2026.103998 and PMC identifier 13240766.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
New chemotherapeutic approaches are still needed to improve survival and quality of life in metastatic pancreatic ductal adenocarcinoma (mPDAC). In the absence of validated predictive biomarkers, first-line sequential treatment strategies may allow to delay chemoresistance and reduce cumulative side effects. PRODIGE 61-FUNGEMAX was an open-label, multicentre, randomised phase II trial conducted in 31 centres in France. Between November 2018 and January 2024, chemotherapy-naive patients aged 18-75 years with histologically confirmed metastatic pancreatic ductal adenocarcinoma (mPDAC) and Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1 were randomly assigned (1:1:1) to receive either nal-IRI (nanoliposomal irinotecan; 70 mg/m<sup>2</sup> intravenously [IV] over 90 min) plus leucovorin (400 mg/m<sup>2</sup> IV over 30 min) and 5-fluorouracil (5-FU; 2400 mg/m<sup>2</sup> IV over 46 h) every 2 weeks (NAPOLI regimen), gemcitabine (1000 mg/m<sup>2</sup> IV over 30 min) plus nab-paclitaxel (125 mg/m<sup>2</sup> IV over 30 min) on days 1, 8, and 15 of a 28-day cycle (MPACT regimen), or both regimens alternating every 2 months (sequential arm). The primary endpoint was the 6-month progression-free survival (PFS) rate, assessed in the modified intention-to-treat (mITT)/safety population (patients who received at least one dose of study treatment). Secondary efficacy analyses were performed in the intention-to-treat (ITT) population. This trial is registered with ClinicalTrials.gov (NCT03693677) and EudraCT (2017-004309-41). Between 16 November 2018 and 25 January 2024, 288 patients were enrolled in 31 French centres. Baseline characteristics were well balanced between the three arms. With a median follow-up of 39.2 months, median treatment durations were 6.3/3.3/5.3 months, for sequential, NAPOLI and MPACT arms, respectively. The 6-month PFS rates were 51.6%, 32.3% and 45.3% in the sequential, NAPOLI and MPACT arms, respectively. Neither sequential (HR = 0.76, p = 0.072) nor NAPOLI regimens (HR = 1.20, p = 0.22) lead to a statistically significant improvement of PFS over the MPACT regimen. The 12-month PFS rates were 20·3%, 12·7%, and 11·9%, and the 24-month OS rates were 23·8%, 9·5%, and 12·5% in the sequential, NAPOLI, and MPACT arms, respectively; these differences were not statistically significant. Safety profiles were consistent with previous publications for each regimen and QoL (QLQ-C30 and EQ5D) was preserved in the sequential arm. The sequential NAPOLI/MPACT regimen seems feasible and tolerable, with higher rates of 12-month PFS and 24-month OS compared with standard MPACT, despite no improvement in median PFS or OS. Future trials should be adequately powered, integrate predictive biomarkers, and include contemporary first-line standards as comparators. This trial was sponsored by the Fédération Francophone de Cancérologie Digestive (FFCD) and supported by a grant from Servier, France.